Century Therapeutics (IPSC) Competitors $0.56 +0.01 (+0.90%) Closing price 07/3/2025 02:21 PM EasternExtended Trading$0.56 0.00 (0.00%) As of 07/3/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC vs. FDMT, IPHA, VTYX, DERM, PBYI, DMAC, SPRO, ALMS, DRUG, and VYGRShould you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), Spero Therapeutics (SPRO), Alumis (ALMS), Bright Minds Biosciences (DRUG), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry. Century Therapeutics vs. Its Competitors 4D Molecular Therapeutics Innate Pharma Ventyx Biosciences Journey Medical Puma Biotechnology DiaMedica Therapeutics Spero Therapeutics Alumis Bright Minds Biosciences Voyager Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Do analysts recommend FDMT or IPSC? 4D Molecular Therapeutics presently has a consensus price target of $29.56, suggesting a potential upside of 621.75%. Century Therapeutics has a consensus price target of $4.20, suggesting a potential upside of 650.00%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than 4D Molecular Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FDMT or IPSC more profitable? Century Therapeutics has a net margin of -19.10% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Century Therapeutics' return on equity of -10.71% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-767,126.06% -33.26% -30.68% Century Therapeutics -19.10%-10.71%-5.96% Do institutionals & insiders hold more shares of FDMT or IPSC? 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 5.0% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor FDMT or IPSC? In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Century Therapeutics. MarketBeat recorded 8 mentions for 4D Molecular Therapeutics and 0 mentions for Century Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.10 beat Century Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Overall Sentiment 4D Molecular Therapeutics Neutral Century Therapeutics Neutral Which has stronger earnings and valuation, FDMT or IPSC? Century Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K4,743.03-$160.87M-$3.18-1.29Century Therapeutics$6.59M7.32-$126.57M-$0.29-1.93 Which has more volatility and risk, FDMT or IPSC? 4D Molecular Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Summary4D Molecular Therapeutics and Century Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPSC vs. The Competition Export to ExcelMetricCentury TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.83M$2.43B$5.53B$9.04BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-1.939.1027.6320.25Price / Sales7.32682.84417.36118.60Price / CashN/A158.5936.8958.07Price / Book0.294.588.035.67Net Income-$126.57M$31.34M$3.18B$249.21M7 Day Performance7.96%3.25%2.91%3.28%1 Month Performance-0.53%7.08%3.72%5.55%1 Year Performance-75.00%0.17%35.14%21.08% Century Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPSCCentury Therapeutics2.7618 of 5 stars$0.56+0.9%$4.20+650.0%-75.3%$47.83M$6.59M-1.93170FDMT4D Molecular Therapeutics2.3078 of 5 stars$3.71-3.4%$29.56+696.6%-80.4%$177.89M$40K-1.17120News CoverageAnalyst ForecastIPHAInnate Pharma2.5563 of 5 stars$1.82-1.9%$11.00+506.1%-15.3%$170.53M$21.77M0.00220Gap DownVTYXVentyx Biosciences2.4175 of 5 stars$2.14-8.5%$10.00+367.3%-5.2%$166.52MN/A-1.2230DERMJourney Medical1.6591 of 5 stars$7.18+0.6%$9.50+32.3%+37.9%$166.33M$56.13M-18.4190PBYIPuma Biotechnology3.9489 of 5 stars$3.43+3.0%$7.00+104.1%+17.5%$165.27M$230.50M4.45200DMACDiaMedica Therapeutics0.9035 of 5 stars$3.90+1.6%$8.00+105.1%+26.3%$164.67MN/A-6.0920SPROSpero Therapeutics3.9181 of 5 stars$2.90-1.4%$5.00+72.4%+119.6%$164.38M$47.98M-2.27150ALMSAlumis3.0979 of 5 stars$3.00-0.7%$22.86+661.9%N/A$164.30MN/A0.00N/ADRUGBright Minds Biosciences2.9164 of 5 stars$26.11+12.2%$83.25+218.8%+2,544.9%$163.91MN/A-72.53N/ANews CoverageAnalyst ForecastAnalyst RevisionVYGRVoyager Therapeutics3.5675 of 5 stars$3.11+5.1%$13.39+330.5%-57.6%$163.80M$80M-2.13100High Trading Volume Related Companies and Tools Related Companies FDMT Alternatives IPHA Alternatives VTYX Alternatives DERM Alternatives PBYI Alternatives DMAC Alternatives SPRO Alternatives ALMS Alternatives DRUG Alternatives VYGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPSC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
